MCID: ATS007
MIFTS: 68

Autism Spectrum Disorder

Categories: Rare diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Autism Spectrum Disorder

MalaCards integrated aliases for Autism Spectrum Disorder:

Name: Autism Spectrum Disorder 12 49 24 50 40 14
Autism Spectrum Disorders 28 69
Asd 49 24
Pervasive Developmental Disorder 24
Pervasive Development Disorder 69
Autistic Continuum 24
Autistic Behavior 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060041

Summaries for Autism Spectrum Disorder

MedlinePlus : 40 Autism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. It affects how a person acts and interacts with others, communicates, and learns. It includes what used to be known as Asperger syndrome and pervasive developmental disorders. It is called a "spectrum" disorder because people with ASD can have a range of symptoms. People with ASD might have problems talking with you, or they might not look you in the eye when you talk to them. They may also have restricted interests and repetitive behaviors. They may spend a lot of time putting things in order, or they may say the same sentence again and again. They may often seem to be in their "own world." At well-child checkups, the health care provider should check your child's development. If there are signs of ASD, your child will have a comprehensive evaluation. It may include a team of specialists, doing various tests and evaluations to make a diagnosis. The causes of ASD are not known. Research suggests that both genes and environment play important roles. There is currently no one standard treatment for ASD. There are many ways to increase your child's ability to grow and learn new skills. Starting them early can lead to better results. Treatments include behavior and communication therapies, skills training, and medicines to control symptoms. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Autism Spectrum Disorder, also known as autism spectrum disorders, is related to asperger syndrome and pervasive developmental disorder, and has symptoms including widespread abnormalities of social interactions, severely restricted interests and highly repetitive behavior. An important gene associated with Autism Spectrum Disorder is EHMT1 (Euchromatic Histone Lysine Methyltransferase 1), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has symptom widespread abnormalities of social interactions and communication, has symptom severely restricted interests and has symptom highly repetitive behavior.

Genetics Home Reference : 24 Autism spectrum disorder (ASD) is a condition that appears very early in childhood development, varies in severity, and is characterized by impaired social skills, communication problems, and repetitive behaviors. These difficulties can interfere with affected individuals' ability to function in social, academic, and employment settings. People with ASD also have an increased risk of psychiatric problems such as anxiety, depression, obsessive-compulsive disorder, and eating disorders.

NIH Rare Diseases : 49 Autism spectrum disorder (ASD) is a condition that affects the development of social and communication skills. It includes features of four conditions which were once thought to be separate syndromes - autistic disorder, Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. Signs and symptoms often become apparent in the first 2-3 years of life and vary significantly from person to person. Common symptoms shared by people with ASD include restrictive and repetitive behaviors, social impairment and communication difficulties. The underlying cause of ASD is generally unknown and it is likely that a variety of factors contribute to the development of the condition. ASD appears to run in some families, suggesting that genetics may play a role in some cases. Although there is no cure for ASD, treatment is available that significantly improves the long-term outlook for affected people. Treatment often includes a combination of techniques such as medications, occupational therapy, speech therapy and physical therapy. Last updated: 12/1/2016

NINDS : 50 Autistic disorder (sometimes called autism or classical ASD) is the most common condition in a group of developmental disorders known as the autism spectrum disorders (ASDs). Autistic children have difficulties with social interaction, display problems with verbal and nonverbal communication, and exhibit repetitive behaviors or narrow, obsessive interests. These behaviors can range in impact from mild to disabling. Autism varies widely in its severity and symptoms and may go unrecognized, especially in mildly affected children or when more debilitating handicaps mask it. Scientists aren’t certain what causes autism, but it’s likely that both genetics and environment play a role.

Related Diseases for Autism Spectrum Disorder

Diseases in the Autism family:

Autism 5 Autism 8
Autism 3 Autism 6
Autism 7 Autism 11
Autism 12 Autism 13
Autism 9 Autism 10
Autism 15 Autism 16
Autism 17 Autism 18
Autism 19 Autism Spectrum Disorder

Diseases related to Autism Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 214, show less)
# Related Disease Score Top Affiliating Genes
1 asperger syndrome 33.1 MECP2 NLGN3 SHANK3
2 pervasive developmental disorder 32.7 CHD8 CNTNAP2 MECP2 NLGN3 NRXN1 PTCHD1
3 autism 32.4 ADNP CHD8 CNTNAP2 EHMT1 HOXA1 MECP2
4 adnp-related intellectual disability and autism spectrum disorder 12.3
5 patent foramen ovale 11.9
6 adnp syndrome 11.8
7 arthrogryposis, mental retardation, and seizures 11.6
8 helsmoortel-van der aa syndrome 11.6
9 timothy syndrome 11.3
10 fragile x syndrome 11.3
11 rett syndrome 11.2
12 chromosome 15q13.3 deletion syndrome 11.2
13 16p11.2 duplication 11.2
14 mental retardation, autosomal recessive 38 11.1
15 mental retardation, autosomal dominant 26 11.1
16 autism x-linked 4 11.0
17 epilepsy, familial focal, with variable foci 1 11.0
18 specific language impairment 5 11.0
19 schaaf-yang syndrome 11.0
20 chromosome 15q11.2 deletion syndrome 11.0
21 neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 11.0
22 childhood disintegrative disease 11.0
23 syngap1-related intellectual disability 11.0
24 autism x-linked 1 10.9
25 autism x-linked 2 10.9
26 autism x-linked 3 10.9
27 autism x-linked 5 10.9
28 autism x-linked 6 10.9
29 chromosome 2q37 deletion syndrome 10.9
30 potocki-shaffer syndrome 10.9
31 athabaskan brainstem dysgenesis syndrome 10.9
32 macrocephaly/autism syndrome 10.9
33 autism 5 10.9
34 autism 8 10.9
35 autism 3 10.9
36 autism 6 10.9
37 autism 7 10.9
38 autism 11 10.9
39 autism 12 10.9
40 potocki-lupski syndrome 10.9
41 autism 13 10.9
42 autism 9 10.9
43 autism 10 10.9
44 autism 15 10.9
45 chromosome 1q21.1 deletion syndrome, 1.35-mb 10.9
46 autism 16 10.9
47 autism 17 10.9
48 chromosome 16p13.3 duplication syndrome 10.9
49 autism 18 10.9
50 luscan-lumish syndrome 10.9
51 epilepsy, familial focal, with variable foci 2 10.9
52 epilepsy, familial focal, with variable foci 3 10.9
53 brachycephaly, trichomegaly, and developmental delay 10.9
54 speech and communication disorders 10.9
55 atypical autism 10.9
56 cask-related disorders 10.9
57 16p11.2 deletion syndrome 10.9
58 17q12 deletion syndrome 10.9
59 autosomal dominant intellectual disability 30 10.9
60 chromosome 3p- syndrome 10.9
61 hivep2-related intellectual disability 10.9
62 syngap1-related non-syndromic intellectual disability 10.9
63 ppp2r5d-related intellectual disability 10.9
64 pitt-hopkins-like syndrome 10.5 CNTNAP2 NRXN1
65 atrial septal defect 1 10.5
66 alacrima, achalasia, and mental retardation syndrome 10.5
67 attention deficit-hyperactivity disorder 10.5
68 aging 10.4
69 disease of mental health 10.4 MECP2 NRXN1 SHANK3
70 anxiety 10.4
71 schizophrenia 10.4
72 mutism 10.3 CNTNAP2 SHANK3
73 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 10.3
74 epilepsy 10.2
75 williams-beuren syndrome 10.2
76 down syndrome 10.1
77 cerebritis 10.1
78 prader-willi syndrome 10.1
79 dysphasia, familial developmental 10.1
80 specific language impairment 10.1
81 developmental coordination disorder 10.1
82 cognitive function 1, social 10.0
83 phelan-mcdermid syndrome 10.0
84 cerebral palsy 10.0
85 fetal alcohol spectrum disorder 10.0
86 tuberous sclerosis 10.0
87 neuronitis 10.0
88 neurofibromatosis, type iv, of riccardi 10.0
89 conduct disorder 10.0
90 dyslexia 10.0
91 learning disability 10.0
92 obsessive-compulsive disorder 9.9
93 tuberous sclerosis 1 9.9
94 parkinson disease 2, autosomal recessive juvenile 9.9
95 branchiootic syndrome 1 9.9
96 bipolar disorder 9.9
97 cornelia de lange syndrome 9.9
98 rubella 9.9
99 childhood-onset schizophrenia 9.9
100 jacobsen syndrome 9.8
101 macrocephaly/megalencephaly syndrome, autosomal recessive 9.8
102 oculocerebral syndrome with hypopigmentation 9.8
103 smith-lemli-opitz syndrome 9.8
104 opitz gbbb syndrome, type i 9.8
105 body mass index quantitative trait locus 11 9.8
106 body mass index quantitative trait locus 9 9.8
107 body mass index quantitative trait locus 8 9.8
108 propionic acidemia 9.8
109 body mass index quantitative trait locus 4 9.8
110 body mass index quantitative trait locus 10 9.8
111 body mass index quantitative trait locus 7 9.8
112 bulimia nervosa 2 9.8
113 body mass index quantitative trait locus 12 9.8
114 body mass index quantitative trait locus 14 9.8
115 body mass index quantitative trait locus 18 9.8
116 hyperprolactinemia 9.8
117 brain injury 9.8
118 oppositional defiant disorder 9.8
119 alexithymia 9.8
120 apraxia 9.8
121 ileocolitis 9.8
122 mumps 9.8
123 gender identity disorder 9.8
124 bipolar i disorder 9.8
125 iron metabolism disease 9.8
126 tic disorder 9.8
127 astrocytoma 9.8
128 pilocytic astrocytoma 9.8
129 borna disease 9.8
130 infertility 9.8
131 sleep disorder 9.8
132 measles 9.8
133 eating disorder 9.8
134 chiari malformation 9.8
135 congenital cytomegalovirus 9.8
136 hyperacusis 9.8
137 autonomic dysfunction 9.8
138 cytomegalovirus infection 9.8
139 megalencephaly 9.8
140 endotheliitis 9.8
141 angelman syndrome 9.7
142 corneal dystrophy, posterior polymorphous, 1 9.7
143 cri-du-chat syndrome 9.7
144 femoral-facial syndrome 9.7
145 li-fraumeni syndrome 9.7
146 migraine with or without aura 1 9.7
147 myotonic dystrophy 1 9.7
148 carney complex, type 1 9.7
149 optic nerve hypoplasia, bilateral 9.7
150 parkinson disease, late-onset 9.7
151 septooptic dysplasia 9.7
152 smith-magenis syndrome 9.7
153 strabismus 9.7
154 cerebrotendinous xanthomatosis 9.7
155 charge syndrome 9.7
156 costello syndrome 9.7
157 hyperlexia 9.7
158 succinic semialdehyde dehydrogenase deficiency 9.7
159 cerebral creatine deficiency syndrome 1 9.7
160 parkinsonism with spasticity, x-linked 9.7
161 muscular dystrophy, duchenne type 9.7
162 nicolaides-baraitser syndrome 9.7
163 xanthomatosis 9.7
164 body mass index quantitative trait locus 1 9.7
165 li-fraumeni syndrome 2 9.7
166 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
167 chromosome 2p16.1-p15 deletion syndrome 9.7
168 trichotillomania 9.7
169 witteveen-kolk syndrome 9.7
170 episodic pain syndrome, familial, 1 9.7
171 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
172 mucopolysaccharidosis-plus syndrome 9.7
173 arthrogryposis multiplex congenita, neurogenic, with myelin defect 9.7
174 syndromic intellectual disability 9.7
175 body dysmorphic disorder 9.7
176 chromosome 15q24 deletion syndrome 9.7
177 osteomyelitis 9.7
178 pre-eclampsia 9.7
179 microphthalmia 9.7
180 separation anxiety disorder 9.7
181 lyme disease 9.7
182 allergic hypersensitivity disease 9.7
183 paranoid schizophrenia 9.7
184 eclampsia 9.7
185 amenorrhea 9.7
186 leopard syndrome 9.7
187 constipation 9.7
188 neonatal jaundice 9.7
189 psychotic disorder 9.7
190 corneal dystrophy 9.7
191 antiphospholipid syndrome 9.7
192 gingivitis 9.7
193 mood disorder 9.7
194 superior mesenteric artery syndrome 9.7
195 placental insufficiency 9.7
196 echolalia 9.7
197 juvenile pilocytic astrocytoma 9.7
198 mitochondrial metabolism disease 9.7
199 axonal neuropathy 9.7
200 neuropathy 9.7
201 muscular dystrophy 9.7
202 myotonic dystrophy 9.7
203 7q11.23 duplication syndrome 9.7
204 mitochondrial disorders 9.7
205 cerebral folate deficiency 9.7
206 chromosome xp deletion 9.7
207 congenital rubella 9.7
208 tetrasomy 9p 9.7
209 developmental dyspraxia 9.7
210 dysautonomia 9.7
211 seizure disorder 9.7
212 spasticity 9.7
213 early-onset schizophrenia 9.7
214 distal trisomy 10q 9.7

Graphical network of the top 20 diseases related to Autism Spectrum Disorder:



Diseases related to Autism Spectrum Disorder

Symptoms & Phenotypes for Autism Spectrum Disorder

Symptoms:

12 (showing 3, show less)
  • widespread abnormalities of social interactions
  • severely restricted interests
  • highly repetitive behavior

UMLS symptoms related to Autism Spectrum Disorder:


pseudobulbar behavioral symptoms, restlessness, personality changes, photophobia, sleep disturbances

MGI Mouse Phenotypes related to Autism Spectrum Disorder:

43 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 CNTNAP2 EHMT1 HOXA1 MECP2 NLGN3 NRXN1
2 growth/size/body region MP:0005378 9.7 SHANK3 CNTNAP2 EHMT1 HOXA1 MECP2 NLGN3
3 nervous system MP:0003631 9.44 NRXN1 PTCHD1 SCN2A SETD2 SHANK1 SHANK2

Drugs & Therapeutics for Autism Spectrum Disorder

Drugs for Autism Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 284, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 20748-11-2, 113-45-1 4158
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 53477758 439302
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
6
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Metformin Approved Phase 4,Phase 3 657-24-9 4091 14219
9
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
10
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106266-06-2 5073
11
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
12
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
13
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
14
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
15
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4
23 gamma-Globulins Phase 4
24 Immunoglobulins Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Rho(D) Immune Globulin Phase 4
27 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
31 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 4,Phase 2
36 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Adrenergic Agonists Phase 4,Phase 2
41 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
42 Adrenergic alpha-Agonists Phase 4,Phase 2
43 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
44 Atomoxetine Hydrochloride Phase 4,Phase 3
45 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
46
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
47 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
49 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
50 Antiemetics Phase 4,Phase 2
51 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
52 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
53 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
54 insulin Phase 4,Phase 2
55 Insulin, Globin Zinc Phase 4,Phase 2
56 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
57 Antimetabolites Phase 4,Phase 3
58 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
59 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
60 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
61 Vasodilator Agents Phase 4,Early Phase 1
62 Antidotes Phase 4,Phase 3,Phase 2
63 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
64 Expectorants Phase 4,Phase 2
65 N-monoacetylcystine Phase 4,Phase 2
66 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
67 Respiratory System Agents Phase 4,Phase 2,Phase 3
68 Hypolipidemic Agents Phase 4
69 Lipid Regulating Agents Phase 4
70 Lisdexamfetamine Dimesylate Phase 4
71 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
72 cysteine Nutraceutical Phase 4,Phase 2
73
Benzocaine Approved, Investigational Phase 2, Phase 3,Phase 1 1994-09-7, 94-09-7 2337
74
Riluzole Approved, Investigational Phase 2, Phase 3 1744-22-5 5070
75
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
76
Diphenhydramine Approved, Investigational Phase 2, Phase 3 58-73-1, 147-24-0 3100
77
Fluoxetine Approved, Vet_approved Phase 2, Phase 3 54910-89-3 3386
78
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
79
Cycloserine Approved Phase 3 68-41-7 6234 401
80
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
81
Ethanol Approved Phase 3,Phase 2 64-17-5 702
82
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
83
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 5460373 44475014 11953898
84
Galantamine Approved Phase 3 357-70-0 9651
85
Secretin Approved, Investigational Phase 3 108153-74-8
86
Bisacodyl Approved Phase 3 603-50-9
87
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
88
Dextromethorphan Approved Phase 2, Phase 3 125-71-3 5362449 5360696
89
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
90
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
91
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
92
Mianserin Approved, Investigational Phase 3 24219-97-4 4184
93
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
94 tannic acid Approved, Nutraceutical Phase 2, Phase 3,Phase 1
95
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
96
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
97
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
98
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3, Phase 1 59-30-3 6037
99
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3 13422-55-4
100
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
101 Hormone Antagonists Phase 3,Phase 2
102 Hormones Phase 3,Phase 2
103 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
104 Anticonvulsants Phase 2, Phase 3
105 Neuroprotective Agents Phase 2, Phase 3
106 Adrenergic beta-Antagonists Phase 2, Phase 3,Early Phase 1
107 Lithium carbonate Phase 2, Phase 3 554-13-2
108 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
109 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
110 Antitubercular Agents Phase 3
111 Renal Agents Phase 3
112 triamcinolone acetonide Phase 3
113 Triamcinolone diacetate Phase 3
114 Triamcinolone hexacetonide Phase 3
115 Fluorodeoxyglucose F18 Phase 3
116 Bone Density Conservation Agents Phase 2, Phase 3
117 Ergocalciferols Phase 2, Phase 3
118 Micronutrients Phase 2, Phase 3, Phase 1, Early Phase 1
119 Trace Elements Phase 2, Phase 3, Phase 1, Early Phase 1
120 Vitamins Phase 2, Phase 3, Phase 1
121 Vitamin B 12 Phase 2, Phase 3
122 Vitamin B Complex Phase 2, Phase 3, Phase 1
123 Dopamine D2 Receptor Antagonists Phase 3,Phase 2,Phase 1
124 Paliperidone Palmitate Phase 3
125 Serotonin 5-HT2 Receptor Antagonists Phase 3,Phase 2,Phase 1
126 Adrenergic alpha-Antagonists Phase 3,Phase 2,Phase 1
127 Adrenergic Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
128
Lurasidone hydrochloride Phase 3,Phase 2,Phase 1 367514-87-2 213046
129 Antidepressive Agents, Second-Generation Phase 3,Phase 2,Phase 1
130 Hematinics Phase 3,Phase 2
131 Antiparasitic Agents Phase 2, Phase 3,Phase 1
132 Antiprotozoal Agents Phase 2, Phase 3,Phase 1
133 Antitussive Agents Phase 2, Phase 3
134 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
135 Antidepressive Agents, Tricyclic Phase 3
136 Histamine Antagonists Phase 3
137 Histamine H1 Antagonists Phase 3
138
Histamine Phosphate Phase 3 51-74-1 65513
139 Epoetin alfa Phase 3 113427-24-0
140 Calciferol Nutraceutical Phase 2, Phase 3
141 Vitamin D2 Nutraceutical Phase 2, Phase 3
142
Cobalamin Nutraceutical Phase 2, Phase 3 13408-78-1 6438156
143 Folate Nutraceutical Phase 2, Phase 3, Phase 1
144 Vitamin B12 Nutraceutical Phase 2, Phase 3
145 Vitamin B9 Nutraceutical Phase 2, Phase 3, Phase 1
146
Naltrexone Approved, Investigational, Vet_approved Phase 1, Phase 2 16590-41-3 5360515
147
Amantadine Approved Phase 2 768-94-5 2130
148
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
149
Iron Approved Phase 2 7439-89-6 23925
150
Baclofen Approved Phase 2,Phase 1 1134-47-0 2284
151
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
152
Suramin Approved, Investigational Phase 1, Phase 2 145-63-1 5361
153
Lenalidomide Approved Phase 2 191732-72-6 216326
154
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
155
Vancomycin Approved Phase 1, Phase 2 1404-90-6 14969 441141
156
Citalopram Approved Phase 2,Phase 1 59729-33-8 2771
157
Quinidine Approved, Investigational Phase 2 56-54-2 441074
158
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
159
Zinc Approved, Investigational Phase 2,Phase 1 7440-66-6 32051 23994
160
Everolimus Approved Phase 2 159351-69-6 6442177
161
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
162
Sertraline Approved Phase 2 79617-96-2 68617
163
Coal tar Approved Phase 2 8007-45-2
164
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078 2978
165
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
166
Bumetanide Approved Phase 2 28395-03-1 2471
167
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 3007 5826
168 Orange Approved, Nutraceutical Phase 2
169
Glutamic Acid Approved, Nutraceutical Phase 2,Early Phase 1 56-86-0 33032
170
B-Carotene Approved, Nutraceutical Phase 2 7235-40-7 5280489
171
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
172
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354